Spots Global Cancer Trial Database for carcinoma in situ
Every month we try and update this database with for carcinoma in situ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | NCT05085990 | Non-muscle Inva... | TARA-002 | 18 Years - | Protara Therapeutics | |
| Localization of Nonpalpable Breast Lesions | NCT01901991 | Breast Cancer Carcinoma in Si... | Radioactive see... Wire-guided loc... | 18 Years - | Rigshospitalet, Denmark | |
| PDT Plus Vitamin D3 for Anal Dysplasia | NCT02698293 | Anal Dysplasia Carcinoma in Si... | Gliolan Vitamin D3 chol... Photodynamic Th... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | NCT05951179 | Non-muscle Inva... | TARA-002 | 18 Years - | Protara Therapeutics | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | NCT04109092 | Urinary Bladder... | E7766 | 18 Years - | Eisai Inc. | |
| Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus | NCT00386594 | Barrett Esophag... | 852A | 18 Years - | Rogers, B.H. Gerald, M.D. | |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) | NCT05085977 | Non-muscle Inva... | TARA-002 | 18 Years - | Protara Therapeutics | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| PDT Plus Vitamin D3 for Anal Dysplasia | NCT02698293 | Anal Dysplasia Carcinoma in Si... | Gliolan Vitamin D3 chol... Photodynamic Th... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) | NCT01316874 | Carcinoma in Si... Bladder Cancer | Valrubicin, 800... | 18 Years - | Endo Pharmaceuticals | |
| Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer | NCT03223753 | Carcinoma In Si... Hematopoietic a... Malignant Solid... | Educational Int... Internet-Based ... Internet-Based ... Laboratory Biom... Medical Device ... Quality-of-Life... Questionnaire A... | 8 Years - 16 Years | Children's Oncology Group | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer | NCT04057209 | Glottis Tumor Larynx Cancer | Single Vocal Co... Arm A: Transora... | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing | NCT04823871 | Ovarian Epithel... Carcinoma in Si... Ovarian Cancer | Speiser-cathete... | 18 Years - 80 Years | Medical University of Vienna | |
| Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma | NCT02039388 | Ovarian Epithel... Carcinoma in Si... Ovarian Cancer | Lavage of the C... | 18 Years - 80 Years | Medical University of Vienna | |
| Localization of Nonpalpable Breast Lesions | NCT01901991 | Breast Cancer Carcinoma in Si... | Radioactive see... Wire-guided loc... | 18 Years - | Rigshospitalet, Denmark | |
| Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus | NCT00386594 | Barrett Esophag... | 852A | 18 Years - | Rogers, B.H. Gerald, M.D. | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | NCT04109092 | Urinary Bladder... | E7766 | 18 Years - | Eisai Inc. | |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | NCT05951179 | Non-muscle Inva... | TARA-002 | 18 Years - | Protara Therapeutics | |
| Phase II Trial of EOquin in High-risk Superficial Bladder Cancer | NCT00141531 | Bladder Neoplas... | Apaziquone | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer | NCT01731652 | Carcinoma in Si... Non Muscle Inva... | TMX-101 | 18 Years - | Telormedix SA | |
| Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | NCT03268993 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol | 18 Years - | University of Pittsburgh | |
| Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists | NCT06056843 | Breast Cancer Carcinoma in Si... | Triage of clini... | 40 Years - 75 Years | International Agency for Research on Cancer | |
| Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions | NCT02217358 | Chronic Inflamm... Hoarseness Macroscopic Lar... Histological Co... Carcinoma in Si... Invasive Carcin... Invasive Carcin... Recurrent Respi... | NBI endoscopy | 30 Years - 80 Years | University Hospital Ostrava | |
| Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | NCT05085990 | Non-muscle Inva... | TARA-002 | 18 Years - | Protara Therapeutics | |
| Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer | NCT03268993 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol | 18 Years - | University of Pittsburgh | |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers | NCT02858310 | Papillomavirus ... Cervical Intrae... Carcinoma In Si... Vulvar Neoplasm... Vulvar Diseases | E7 TCR cells Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions | NCT02217358 | Chronic Inflamm... Hoarseness Macroscopic Lar... Histological Co... Carcinoma in Si... Invasive Carcin... Invasive Carcin... Recurrent Respi... | NBI endoscopy | 30 Years - 80 Years | University Hospital Ostrava | |
| Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists | NCT06056843 | Breast Cancer Carcinoma in Si... | Triage of clini... | 40 Years - 75 Years | International Agency for Research on Cancer | |
| Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer | NCT03182959 | HNSCC Head and Neck C... Head and Neck S... Tobacco-Related... Carcinoma in Si... Dysplasia Hyperplasia Premalignant Le... | Avmacol® | 18 Years - | University of Arizona | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
